SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Marksans Pharma informs about board meeting

08 May 2025 Evaluate
Marksans Pharma has informed that the meeting of the Board of Directors of the Company is scheduled on 19/05/2025, to consider and approve the Audited Financial Results of the Company (both Standalone and Consolidated) for the Quarter and Year ended March 31, 2025; To consider recommendation of dividend on the equity shares for the financial year 2024-25, if any.

The above information is a part of company’s filings submitted to BSE.

Marksans Pharma Share Price

266.50 2.50 (0.95%)
06-Jul-2026 10:14 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1908.70
Dr. Reddys Labs. 1368.95
Cipla 1456.10
Zydus Lifesciences 1134.45
Lupin 2484.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: